Advertisement

Drug Safety

, Volume 37, Issue 4, pp 259–268 | Cite as

Application of a Self-Controlled Case Series Study to a Database Study in Children

  • Hanae Ueyama
  • Shiro Hinotsu
  • Shiro Tanaka
  • Hisashi Urushihara
  • Masaki Nakamura
  • Yuji Nakamura
  • Koji KawakamiEmail author
Original Research Article

Abstract

Introduction

Post-marketing surveillance activities are particularly important for safety issues in children, the elderly, and patients with severe comorbidities since these populations are usually excluded from clinical trials. In addition, using electronic databases for monitoring of safety of marketed products has been of considerable interest.

Objectives

This study aimed to clarify the advantages and difficulties of the self-controlled case series method relative to cohort studies in pharmacoepidemiological studies in children, using an administrative database, and to explore the impact on results of handling the period eligible for analysis and recurrent events in different ways.

Methods

Datasets of only individuals who had the outcome of interest were derived from an anonymized hospital administrative database in Japan from April 2003 through August 2011. We calculated incidence rate ratios (IRRs) and their 95 % confidence intervals (CIs) for the risks of diarrhea, bronchitis, and eczema related to palivizumab treatment in young children. The analysis included ‘first diagnosed’ events or ‘multiple’ events during an eligible period. An eligible period was defined in two ways: first-time inpatient periods of more than 3 continuous days (EPA); and a continuous period in cases where the interval between visits was below the 75th percentile of the interval between visits for patients with the same diagnosis (EPB).

Results

We extracted data for 70,771 patients and identified 641 who were exposed to palivizumab. The age-adjusted IRRs for diarrhea, bronchitis, and eczema were 3.0 (95 % CI 1.7–5.4), 10.3 (95 % CI 8.0–13.2), and 16.9 (95 % CI 12–23), respectively, in multiple events and the EPB eligible period. The IRRs varied greatly between the two eligible periods.

Conclusions

This method could be a useful tool in pharmacoepidemiological studies in children. Careful consideration in the handling of inpatient and outpatient periods, including sensitivity analyses, is necessary because this method is a within-individual comparison.

Keywords

Palivizumab Clinical Practice Research Datalink Pharmacoepidemiological Study Diagnosis Procedure Combination Eligible Period 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflicts of interest

This work was supported by a 2011 Research Grant from Pfizer Health Research Foundation (10-8-043) http://www.pfizer-zaidan.jp/. This report was co-authored by academic researchers and Medical Data Vision Co., Ltd (MDV). HU, SH, and KK have no conflicts of interest regarding MDV. Hanae Ueyama, Shiro Hinotsu, Shiro Tanaka, Hisashi Urushihara, Masaki Nakamura, Yuji Nakamura and Koji Kawakami have no conflicts of interest with any other organization related to the subject of this report.

References

  1. 1.
    Coloma PM, Schuemie MJ, Trifiro G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR project. Pharmacoepidemiol Drug Saf. 2011;20(1):1–11.CrossRefPubMedGoogle Scholar
  2. 2.
    Linder JA, Haas JS, Iyer A, et al. Secondary use of electronic health record data: spontaneous triggered adverse drug event reporting. Pharmacoepidemiol Drug Saf. 2010;19(12):1211–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Bello A, Hemmelgarn B, Manns B, Tonelli M, for Alberta Kidney Disease Network. Use of administrative databases for health-care planning in CKD. Nephrol Dial Transplant. 2012; doi: 10.1093/ndt/gfs163.
  4. 4.
    Smoyer Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, medicare supplemental insured, and medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord. 2012;13(1):103.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Smith EG, Zhao S, Rosen AK. Using the patient safety indicators to detect potential safety events among US veterans with psychotic disorders: clinical and research implications. Int J Qual Health Care. 2012;24(4):321–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Schoonen WM, Thomas SL, Somers EC, et al. Do selected drugs increase the risk of lupus? A matched case-control study. Br J Clin Pharmacol. 2010;70(4):588–96.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Gibson JE, Hubbard RB, Smith CJ, Tata LJ, Britton JR, Fogarty AW. Use of self-controlled analytical techniques to assess the association between use of prescription medications and the risk of motor vehicle crashes. Am J Epidemiol. 2009;169(6):761–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25(4):1019–27.CrossRefPubMedGoogle Scholar
  9. 9.
    Ministry of Health, Labour and Welfare (MHLW). National database guideline in Japan (in Japanese). Available: http://www.mhlw.go.jp/stf/shingi/2r98520000016v8d-att/2r98520000016vcn.pdf. Accessed Aug 29 2013.
  10. 10.
    Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010;20(5):413–9.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Akazawa M, Imai H, Igarashi A, Tsutani K. Potentially inappropriate medication use in elderly Japanese patients. Am J Geriatr Pharmacother. 2010;8(2):146–60.CrossRefPubMedGoogle Scholar
  12. 12.
    Hashikata H, Harada KH, Kagimura T, Nakamura M, Koizumi A. Usefulness of a large automated health records database in pharmacoepidemiology. Environ Health Prev Med. 2011;16(5):313–9.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:a1227.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Pratt NL, Roughead EE, Ramsay E, Salter A, Ryan P. Risk of hospitalization for stroke associated with antipsychotic use in the elderly: a self-controlled case series. Drugs Aging. 2010;27(11):885–93.CrossRefPubMedGoogle Scholar
  15. 15.
    Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10):1768–97.CrossRefPubMedGoogle Scholar
  16. 16.
    The IMpact-RSV study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3 Pt 1):531–7.CrossRefGoogle Scholar
  17. 17.
    Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532–40.CrossRefPubMedGoogle Scholar
  18. 18.
    Maclure M, Fireman B, Nelson JC, et al. When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Saf. 2012;21(S1):50–61.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Hanae Ueyama
    • 1
  • Shiro Hinotsu
    • 1
  • Shiro Tanaka
    • 1
  • Hisashi Urushihara
    • 1
  • Masaki Nakamura
    • 2
  • Yuji Nakamura
    • 2
  • Koji Kawakami
    • 1
    Email author
  1. 1.Department of Pharmacoepidemiology, Graduate School of Medicine and Public HealthKyoto UniversityKyotoJapan
  2. 2.Medical Data Vision Co., LtdTokyoJapan

Personalised recommendations